Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07191483

A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of KYN-5356 as Adjunctive Treatment in Adults With Cognitive Impairment Associated With Schizophrenia

Status
Recruiting
Phase
Phase 2
Study type
Interventional
Enrollment
150 (estimated)
Sponsor
Kynexis B.V. · Industry
Sex
All
Age
18 Years – 55 Years
Healthy volunteers
Not accepted

Summary

This is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, Pharmacokinetic (PK) and Pharmacodynamic (PD) effects of 3 different dose regiments of KYN-5356 and placebo for 28 days. Participants will be randomized to one of 4 treatment groups: placebo, KYN-5356 low dose, KYN-5356 medium dose, KYN-5356 high dose. Participants will be admitted to the clinic on Day -3 and will remain in residence at the clinic for 32 days, from baseline through the treatment period. Participants will be administered investigational medicinal product on Days 1 through 28. Efficacy, safety, PK and exploratory PD assessments will be performed throughout the dosing period. Participants will be discharged on Day 29 after safety assessments are completed and return for a follow-up visit on Day 42. A subset of participants from selected sites will undergo electrophysiological assessments to evaluate the effect of KYN-5356 on neurophysiological measures of brain function.

Conditions

Interventions

TypeNameDescription
DRUGKYN-5356 low doseoral tablet
OTHERPlaceboOral tablet
DRUGKYN-5356 Medium Doseoral tablet
DRUGKYN-5356 High Doseoral tablet

Timeline

Start date
2025-08-27
Primary completion
2025-10-01
Completion
2026-12-01
First posted
2025-09-24
Last updated
2025-09-25

Locations

13 sites across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT07191483. Inclusion in this directory is not an endorsement.